ENXTPA:GBT

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Guerbet SA engages in the research, development, production, and sale of contrast media products, delivery systems, medical devices, and related solutions worldwide.

Rewards

Loading...

Risk Analysis

Loading...

Snowflake Analysis

Adequate balance sheet average dividend payer.


Similar Companies

Share Price & News

How has Guerbet's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-1.8%

GBT

-0.4%

FR Medical Equipment

-1.9%

FR Market


1 Year Return

-39.4%

GBT

64.4%

FR Medical Equipment

-9.3%

FR Market


Shareholder returns

GBTIndustryMarket
7 Day-1.8%-0.4%-1.9%
30 Day-6.4%11.2%-2.4%
90 Day10.0%23.4%10.6%
1 Year-38.1%-39.4%64.8%64.4%-7.4%-9.3%
3 Year-57.7%-59.9%64.4%61.6%8.5%-0.5%
5 Year-15.5%-21.6%158.3%151.0%22.4%5.7%

Price Volatility Vs. Market

How volatile is Guerbet's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Guerbet undervalued compared to its fair value and its price relative to the market?

11.16x

Price to Earnings (PE) ratio


Share Price vs. Fair Value


Price To Earnings Ratio


Price to Earnings Growth Ratio


Price to Book Ratio


Next Steps

Future Growth

How is Guerbet forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

1.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts


Earnings per Share Growth Forecasts


Future Return on Equity


Next Steps

Past Performance

How has Guerbet performed over the past 5 years?

7.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis


Return on Equity


Next Steps

Financial Health

How is Guerbet's financial position?


Financial Position Analysis


Debt to Equity History and Analysis


Balance Sheet


Next Steps

Dividend

What is Guerbet current dividend yield, its reliability and sustainability?

2.11%

Current Dividend Yield


Dividend Yield vs Market


Stability and Growth of Payments


Current Payout to Shareholders


Future Payout to Shareholders


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure


CEO

David Hale (51yo)

0.50

Tenure

Mr. David Hale has been Chief Executive Officer of Guerbet SA since January 1, 2020. Mr. Hale served as Chief Commercial Officer of Guerbet SA since 2019 until January 1, 2020 and served as its Chief Comme ...


Leadership Team

NamePositionTenureCompensationOwnership
Pierre André
Chief Pharmaceutical Officer & Deputy CEO4.25yrs€236.95kno data
David Hale
Chief Executive Officer0.50yrno datano data
Jérôme Estampes
Chief Financial Officer1.25yrsno datano data
Elena Puntorieri
Vice President of Purchasing & Member of Management Boardno datano datano data
Anne-Laure Delasalle
Vice President of Communications & Imageno datano datano data
Antoine Mazraani
VP of European Operations & Member of Management Boardno datano datano data
Alain Le Jeune
Member of Management Boardno datano datano data
Frédéric Duchet
Chief Information Officer & Member of Management Boardno datano datano data
Petra Zalabak
Vice President of Human Resources0.50yrno datano data
François Nicolas
Chief Digital Officer and VP of Contrast Injection Systems R&D2.83yrsno datano data

1.3yrs

Average Tenure

51yo

Average Age


Board Members

NamePositionTenureCompensationOwnership
Marion Barbier
Non-Independent Director9yrs€24.00kno data
Thibault Viort
Independent Director3.17yrs€25.50kno data
Michel Guerbet
Honorary Chairmanno data€18.96k54.87% 228.0m
Marie-Claire Janailhac-Fritsch
Independent Chairwoman of the Board6.83yrs€124.13kno data
Claire Jouault-Massiot
Non-Independent Director7.17yrs€27.00kno data
Mark Fouquet
Non-Independent Director6.17yrs€26.00kno data
Didier Izabel
Independent Director6.17yrs€37.50kno data
Céline Lamort
Non-Independent Director5.17yrs€23.00kno data
Nicolas Louvet
Non-Independent Director4.17yrs€24.00kno data
Eric Guerbet
Non-Independent Director3.17yrs€22.50kno data

6.2yrs

Average Tenure

59yo

Average Age


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume


Ownership Breakdown


Top Shareholders

Company Information

Guerbet SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Guerbet SA
  • Ticker: GBT
  • Exchange: ENXTPA
  • Founded: 1926
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: €415.486m
  • Shares outstanding: 12.55m
  • Website: https://www.guerbet.com

Number of Employees


Location

  • Guerbet SA
  • 15, rue des Vanesses
  • Zone Paris Nord II
  • Villepinte
  • Ile-de-France
  • 93420
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
GUER.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJan 1992
GBTENXTPA (Euronext Paris)YesOrdinary SharesFREURJan 1992
0ELVLSE (London Stock Exchange)YesOrdinary SharesGBEURJan 1992
4G8DB (Deutsche Boerse AG)YesOrdinary SharesDEEURJan 1992
GBTPBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBEURJan 1992

Biography

Guerbet SA engages in the research, development, production, and sale of contrast media products, delivery systems, medical devices, and related solutions worldwide. Its products for the CT and Cath Lab examinations include Optiray, a low osmolar contrast medium; Xenetix, a low-osmolar iodinated agent; Telebrix, a high osmolar contrast medium; Conray and MD high osmolar contrast medium products; and high osmolar contrast medium, an ionic low osmolar contrast medium agent. The company’s products for the magnetic resonance imaging (MRI) examinations comprise Dotarem, a non-specific gadolinium-based contrast medium; Artirem products; and Optimark, a contrast medium. In addition, it provides products for interventional imaging, including Lipiodol ethyl esters of iodinated fatty acids of poppy seed oil; Vectorio, a classic transarterial chemoembolization mixing and injection system; and Patent Blue V, an injectable medium. Further, the company offers delivery systems and services comprising injectors; consumables for various types of injectors; and Contrast&Care, a patient data management software. The company distributes its products directly, as well as through distributors and license-holders primarily to hospitals, clinics, radiology centers, purchasing pools, and wholesalers. Guerbet SA was founded in 1926 and is headquartered in Villepinte, France. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/09 20:55
End of Day Share Price2020/07/09 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.